The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Apart from mistrust in the larger pharmaceutical world and Pfizer's inability to find a major break after the pandemic ...

Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

Hedge fund Starboard Value's activist campaign targeting Pfizer (PFE) divides Wall Street, with analysts questioning the ...